New shot for vitiligo shows promise in early trial
NCT ID NCT06625177
First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 25 times
Summary
This early-stage trial tests a new drug called TEV-53408 in 38 adults with vitiligo, a condition that causes white patches on the skin. The main goal is to see if the drug is safe. Participants receive injections for 24 weeks and are followed for over a year. This study does not aim to cure vitiligo, but to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VITILIGO are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Teva Investigational Site 12043
Scottsdale, Arizona, 85260, United States
-
Teva Investigational Site 12044
Fremont, California, 94538, United States
-
Teva Investigational Site 12045
Dallas, Texas, 75230, United States
-
Teva Investigational Site 12046
Pasadena, California, 91101, United States
-
Teva Investigational Site 12047
Chicago, Illinois, 60614, United States
-
Teva Investigational Site 12048
Canton, Michigan, 48187, United States
-
Teva Investigational Site 12049
Miramar, Florida, 33025, United States
-
Teva Investigational Site 12051
Irvine, California, 92617, United States
-
Teva Investigational Site 12052
Hot Springs, Arkansas, 71913, United States
-
Teva Investigational Site 12053
Louisville, Kentucky, 40421, United States
-
Teva Investigational Site 12054
Portland, Oregon, 97210, United States
-
Teva Investigational Site 12055
South Jordan, Utah, 84095, United States
-
Teva Investigational Site 12057
Webster, Texas, 77598, United States
Conditions
Explore the condition pages connected to this study.